Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maryam Mooghali

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
JCO Oncology Practice|April 1, 2026
When Priority Review No Longer PrioritizesMaryam Mooghali, Aaron P Mitchell
BMC Complementary Medicine and Therapies|July 31, 2020
eHealth technologies assisting in identifying potential adverse interactions with complementary and alternative medicine (CAM) or standalone CAM adverse events or side effects: a scoping reviewJeremy Y Ng, Maryam Mooghali, Vanessa Munford
BMJ Open|October 26, 2024
Direct oral anticoagulant approvals by four major regulatory agencies: a cross-sectional analysis of premarket and postmarket evidenceMaryam Mooghali, Tianna Zhou, Joseph S Ross
Journal of the National Cancer Institute|August 26, 2025
Industry promotion of oncology drugs with accelerated approval that failed confirmatory trialsMaryam Mooghali, Reshma Ramachandran, Ayman Mohammad, et al.
BMJ Open|January 23, 2023
Financial conflicts of interest among US physician authors of 2020 clinical practice guidelines: a cross-sectional studyMaryam Mooghali, Laura Glick, Reshma Ramachandran, et al.
JAMA|November 13, 2024
Representativeness of Studies Required Under Medicare's Coverage With Evidence Development ProgramMaryam Mooghali, Sanket S Dhruva, Joseph S Ross, et al.
JAMA Network Open|August 27, 2024
Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough TherapiesMaryam Mooghali, Joshua D Wallach, Joseph S Ross, et al.
JAMA Internal Medicine|May 15, 2023
Availability of Unique Device Identifiers for Class I Medical Device Recalls From 2018 to 2022Maryam Mooghali, Joseph S Ross, Kushal T Kadakia, et al.
Medical Devices (Auckland, N.Z.)|May 25, 2023
Characterization of US Food and Drug Administration Class I Recalls from 2018 to 2022 for Moderate- and High-Risk Medical Devices: A Cross-Sectional StudyMaryam Mooghali, Joseph S Ross, Kushal T Kadakia, et al.
JAMA Network Open|August 31, 2023
Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel TherapeuticsAlissa K Wong, Maryam Mooghali, Reshma Ramachandran, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
JCO Oncology Practice|April 1, 2026
When Priority Review No Longer PrioritizesMaryam Mooghali, Aaron P Mitchell
BMC Complementary Medicine and Therapies|July 31, 2020
eHealth technologies assisting in identifying potential adverse interactions with complementary and alternative medicine (CAM) or standalone CAM adverse events or side effects: a scoping reviewJeremy Y Ng, Maryam Mooghali, Vanessa Munford
BMJ Open|October 26, 2024
Direct oral anticoagulant approvals by four major regulatory agencies: a cross-sectional analysis of premarket and postmarket evidenceMaryam Mooghali, Tianna Zhou, Joseph S Ross
Journal of the National Cancer Institute|August 26, 2025
Industry promotion of oncology drugs with accelerated approval that failed confirmatory trialsMaryam Mooghali, Reshma Ramachandran, Ayman Mohammad, et al.
BMJ Open|January 23, 2023
Financial conflicts of interest among US physician authors of 2020 clinical practice guidelines: a cross-sectional studyMaryam Mooghali, Laura Glick, Reshma Ramachandran, et al.
JAMA|November 13, 2024
Representativeness of Studies Required Under Medicare's Coverage With Evidence Development ProgramMaryam Mooghali, Sanket S Dhruva, Joseph S Ross, et al.
JAMA Network Open|August 27, 2024
Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough TherapiesMaryam Mooghali, Joshua D Wallach, Joseph S Ross, et al.
JAMA Internal Medicine|May 15, 2023
Availability of Unique Device Identifiers for Class I Medical Device Recalls From 2018 to 2022Maryam Mooghali, Joseph S Ross, Kushal T Kadakia, et al.
Medical Devices (Auckland, N.Z.)|May 25, 2023
Characterization of US Food and Drug Administration Class I Recalls from 2018 to 2022 for Moderate- and High-Risk Medical Devices: A Cross-Sectional StudyMaryam Mooghali, Joseph S Ross, Kushal T Kadakia, et al.
JAMA Network Open|August 31, 2023
Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel TherapeuticsAlissa K Wong, Maryam Mooghali, Reshma Ramachandran, et al.
Pageof 3